Outer Biosciences Uses Living Human Skin and AI to Accelerate Skincare Discovery

Outer Biosciences, an AI and biotechnology startup founded by Michael Polansky, has revealed its work using discarded living human skin tissue to train predictive artificial intelligence models for skincare discovery. By sustaining living tissue outside the body for up to a month, the company aims to test biological responses and identify active cosmetic ingredients faster than conventional laboratory methods.

What Happened

Founded in 2022, Outer Biosciences developed a system to keep human skin tissue alive outside the body for up to 30 days, compared to the conventional laboratory standard of just a few days. The startup sources skin that would otherwise be discarded after surgical procedures, predominantly plastic surgery, through vetted biobanks and tissue brokers under institutional review board oversight and documented donor consent.

The company receives de-identified tissue within hours of surgery and maintains it using a proprietary support mechanism that supplies nutrients while removing metabolic waste. Researchers observe long-term biological processes—such as barrier repair, pigmentation changes, and UV stress—and feed the resulting data into an AI model. The AI suggests untested compounds likely to yield specific skin benefits, tests them on the living tissue, and continuously refines its predictions through this feedback loop.

Key Highlights

• Extended Tissue Viability: Outer Biosciences maintains living human tissue for up to a month, allowing researchers to study complex biological processes like collagen remodeling and barrier recovery.
• Closed-Loop AI Architecture: The company pairs living tissue experiments with predictive AI models running on-premise, generating a new candidate compound approximately every six weeks.
• Ethical Sourcing Protocols: Samples are acquired on a cost-recovery basis from suppliers including the National Disease Research Interchange and the Cooperative Human Tissue Network, with direct identifiers removed upstream.
• Targeting Cosmetic Ingredients: The firm focuses on cosmetic compounds rather than prescription drugs, pursuing international safety evaluations under OECD guidelines rather than lengthy FDA drug-approval pathways.
• Corporate and Advisory Links: The 19-person company has raised roughly $23 million from backers including Calm Capital, Brighter Capital, and Hawktail. Board members include Stefani Germanotta (Lady Gaga), whose cosmetics enterprise, Haus Labs, shares collaborative advisory ties with the startup.

Why This Matters

Traditional preclinical biological research often relies on animal models, simplified cell cultures, or synthetic organoids, which do not fully replicate the behavior of living human organs. Direct testing on human subjects also faces severe ethical and safety boundaries. By prolonging the viable life of real human skin, Outer Biosciences creates an experimental environment where biological reactions unfold naturally over weeks. Because the global inventory of proven active skincare ingredients remains relatively small—estimated by Polansky at around 200, including cosmetic substances backed by research—the automated discovery loop offers a systematic method to evaluate new compounds without synthetic approximations.

What to Watch Next

Outer Biosciences plans to establish a dedicated product-development team to oversee downstream formulation, safety testing, and manufacturing scale-up, tasks currently handled manually by its research scientists. Four of the company’s six active leads are expected to move toward commercialization through licensing deals or partnerships with beauty and pharmaceutical brands rather than an in-house consumer label. The company also continues collaborative research examining adverse skin reactions caused by specific cancer therapies.

Frequently Asked Questions

How does Outer Biosciences obtain human skin tissue?

The startup sources skin discarded from surgical procedures—primarily plastic surgery—via brokers and biobanks operating under institutional review board oversight, such as the Cooperative Human Tissue Network and the National Disease Research Interchange. Donors provide consent, and identifying details are removed before the tissue reaches the lab.

Why is keeping tissue alive for 30 days significant?

Typical laboratory tissue protocols preserve viability for only a few days, which is sufficient for measuring acute toxicity but too brief to observe gradual biological changes. Sustaining tissue for up to a month allows researchers to observe prolonged cellular events, including UV recovery, pigmentation shifts, and collagen remodeling.

Does Outer Biosciences plan to release its own consumer skincare line?

According to founder Michael Polansky, the startup intends to license or sell its discovered ingredients to external pharmaceutical and beauty companies rather than launching a standalone consumer brand.

Source: TechCrunch interview and company disclosures.